These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8446933)

  • 1. The development of homologous (canine/anti-canine) antibodies in dogs with haemophilia A (factor VIII deficiency): a ten-year longitudinal study.
    Tinlin S; Webster S; Giles AR
    Thromb Haemost; 1993 Jan; 69(1):21-4. PubMed ID: 8446933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indirect carrier detection of canine haemophilia A using factor VIII microsatellite markers.
    Brooks MB; MacNguyen R; Hall R; Gupta R; Booth JG
    Anim Genet; 2008 Jun; 39(3):278-83. PubMed ID: 18454805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the cuticle bleeding time in canine haemophilia A.
    Pijnappels MI; Briët E; van der Zwet GT; Huisden R; van Tilburg NH; Eulderink F
    Thromb Haemost; 1986 Feb; 55(1):70-3. PubMed ID: 3085267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development and characterisation of antibodies to human factor VIII in haemophilic dogs.
    Littlewood JD; Barrowcliffe TW
    Thromb Haemost; 1987 Jun; 57(3):314-21. PubMed ID: 3116702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haemophilia A (factor VIII deficiency) in a litter of Weimaraners.
    Dunning MD; Averis GF; Pattinson H; Targett M; Cade S; Herrtage ME
    J Small Anim Pract; 2009 Jul; 50(7):357-9. PubMed ID: 19508492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.
    Hay CR; Ludlam CA; Colvin BT; Hill FG; Preston FE; Wasseem N; Bagnall R; Peake IR; Berntorp E; Mauser Bunschoten EP; Fijnvandraat K; Kasper CK; White G; Santagostino E
    Thromb Haemost; 1998 Apr; 79(4):762-6. PubMed ID: 9569189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
    Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
    J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593-->Cys substitution.
    van den Brink EN; Timmermans SM; Turenhout EA; Bank CM; Fijnvandraat K; Voorberg J; Peters M
    Thromb Haemost; 1999 May; 81(5):723-6. PubMed ID: 10365744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
    Reipert BM; van Helden PM; Schwarz HP; Hausl C
    Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype.
    Jarvis MA; Levin LG; Harrison JA; DePianto DJ; Suzuki CM; Ziaja CL; Brown JE; Jolly KW; Reisner HM; Abildgaard CF; Powell JS
    Thromb Haemost; 1996 Feb; 75(2):318-25. PubMed ID: 8815584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The effect of factor VIII:C activity on the activated partial thromboplastin time (aPTT) in the dog. Adaptation of the aPTT as a screening test for canine hemophilia A?].
    Mischke R
    Dtsch Tierarztl Wochenschr; 1993 Jun; 100(6):219-22. PubMed ID: 8339706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitor development in one patient and laboratory discrepancies in several families with both mild haemophilia and Arg531Cys mutation.
    Cid AR; Casaña P; Cabrera N; Haya S; Cortina V; Aznar JA
    Haemophilia; 2007 Mar; 13(2):206-8. PubMed ID: 17286776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired haemophilia: functional study of antibodies to Factor VIII.
    Allain JP; Gaillandre A; Frommel D
    Thromb Haemost; 1981 Jun; 45(3):285-9. PubMed ID: 6792741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors.
    Unuvar A; Kavakli K; Baytan B; Kazanci E; Sayli T; Oren H; Celkan T; Gursel T
    Haemophilia; 2008 Mar; 14(2):315-22. PubMed ID: 18081830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological aspects of inhibitor development.
    Reding MT
    Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of factor VIII antibody in haemophilic monozygotic twins. European Study Group of Factor VIII Antibody.
    Scand J Haematol; 1979 Jul; 23(1):64-8. PubMed ID: 573920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies to factor VIII in hemophilia A patients.
    Brackmann HH; Schwaab R; Effenberger W; Hess L; Hanfland P; Oldenburg J
    Vox Sang; 2000; 78 Suppl 2():187-90. PubMed ID: 10938950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A.
    Bi L; Lawler AM; Antonarakis SE; High KA; Gearhart JD; Kazazian HH
    Nat Genet; 1995 May; 10(1):119-21. PubMed ID: 7647782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of inhibitors in mild/moderate haemophilia A.
    Peerlinck K; Jacquemin M
    Haemophilia; 2006 Dec; 12 Suppl 6():43-7. PubMed ID: 17123393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in the treatment of high responding inhibitors in severe haemophilia A.
    Moschovi M; Aronis S; Trimis G; Platokouki H; Salavoura K; Tzortzatou-Stathopoulou F
    Haemophilia; 2006 Jan; 12(1):95-9. PubMed ID: 16409183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.